Kaneh Bosm BioTechnology Inc. (the "Company") (CSE: KBB) Closing Financing for $4,007,500

/NOT FOR DISSEMINATION IN THE UNITED STATES/

VANCOUVER, April 6, 2018 /CNW/ - Kaneh Bosm BioTechnology Inc. (KBB:CSE) ("Kaneh Bosm" or the "Company") announces the Company has closed its previously announced non-brokered private placement consisting of 16,030,000 units for gross proceeds $4,007,500 at a price of $0.25 per unit.

Each unit will comprise one common share of the issuer and one common share purchase warrant of the issuer. Each warrant will be exercisable into a common share of the company at an exercise price of 50 cents with a two-year expiry. The proceeds of the private placement will be used for general working capital and potential acquisitions. No finder's fees have been paid or issued in regards to the private placement.

All securities issued in connection with the offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities law. The offering and consolidation are subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including approval of the CSE Exchange.

On behalf of the Board of Directors of Kaneh Bosm Biotechnology Inc.

"Rudy de Jonge"

Rudy de Jonge
CEO, Director
[email protected]
(604) 782-4191

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

This news release includes certain statements that may be deemed "forward-looking statements". The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com

SOURCE Kaneh Bosm Biotechnology Inc.